{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:55:12Z","timestamp":1792896912072,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ijrobp.2017.11.029","type":"journal-article","created":{"date-parts":[[2017,11,25]],"date-time":"2017-11-25T01:02:23Z","timestamp":1511571743000},"page":"906-915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Phase 1 Dose Escalation Trial of Ipilimumab and\u00a0Stereotactic Body Radiation Therapy in Metastatic Melanoma"],"prefix":"10.1016","volume":"100","author":[{"given":"Nora","family":"Sundahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien","family":"De Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel","family":"Meireson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dries","family":"Reynders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8896-0721","authenticated-orcid":false,"given":"Els","family":"Goetghebeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"Van Gele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhart","family":"Speeckaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Hennart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieve","family":"Brochez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2017.11.029_bib1","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.molonc.2014.07.011","article-title":"Acquired and intrinsic resistance in cancer immunotherapy","volume":"8","author":"Kelderman","year":"2014","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib2","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.tips.2013.10.003","article-title":"Challenging resistance mechanisms to therapies for metastatic melanoma","volume":"34","author":"Tentori","year":"2013","journal-title":"Trends Pharmacol Sci"},{"issue":"Suppl. 3","key":"10.1016\/j.ijrobp.2017.11.029_bib3","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1053\/j.seminoncol.2015.10.002","article-title":"Immunotherapy combinations with checkpoint inhibitors in metastatic melanoma: Current approaches and future directions","volume":"42","author":"Atkins","year":"2015","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib5","doi-asserted-by":"crossref","first-page":"653","DOI":"10.18553\/jmcp.2017.23.6.653","article-title":"Cost-effectiveness of nivolumab-ipilimumab combination therapy compared with monotherapy for first-line treatment of metastatic melanoma in the United States","volume":"23","author":"Oh","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib6","doi-asserted-by":"crossref","first-page":"e1046028","DOI":"10.1080\/2162402X.2015.1046028","article-title":"A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab","volume":"4","author":"Chandra","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib7","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","article-title":"Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer","volume":"11","author":"Demaria","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib8","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib9","doi-asserted-by":"crossref","first-page":"e28780","DOI":"10.4161\/onci.28780","article-title":"Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy","volume":"3","author":"Grimaldi","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib10","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijrobp.2016.04.017","article-title":"Safety and efficacy of radiation therapy in advanced melanoma patients treated with ipilimumab","volume":"96","author":"Qin","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib12","doi-asserted-by":"crossref","first-page":"1117P","DOI":"10.1093\/annonc\/mdw379.12","article-title":"A dose escalation phase 1 study of radiotherapy (RT) in combination with anti-cytotoxic-t-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody ipilimumab (IPI) in patients (pts) with metastatic melanoma","volume":"27","author":"Boutros","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib13","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4049\/jimmunol.1200563","article-title":"Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation","volume":"189","author":"Gupta","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib14","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ijrobp.2016.07.005","article-title":"A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma","volume":"96","author":"Hiniker","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib15","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ijrobp.2011.09.049","article-title":"Maximizing tumor immunity with fractionated radiation","volume":"83","author":"Schaue","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib17","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib18","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S1470-2045(12)70510-7","article-title":"Stereotactic body radiotherapy for oligometastases","volume":"14","author":"Tree","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib19","doi-asserted-by":"crossref","first-page":"e1042198","DOI":"10.1080\/2162402X.2015.1042198","article-title":"The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy","volume":"4","author":"De Wolf","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib20","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/1479-5876-12-191","article-title":"Ipilimumab augments antitumor activity of bispecific antibody-armed t cells","volume":"12","author":"Yano","year":"2014","journal-title":"J Transl Med"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib23","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.0006-341X.2000.01177.x","article-title":"Sequential designs for phase I clinical trials with late-onset toxicities","volume":"56","author":"Cheung","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib24","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: The report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib25","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib26","doi-asserted-by":"crossref","first-page":"e982382","DOI":"10.4161\/2162402X.2014.982382","article-title":"Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma","volume":"4","author":"Chevolet","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib27","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.ijrobp.2012.02.051","article-title":"A phase I\/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer","volume":"84","author":"Ben-Josef","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib28","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1200\/JCO.2005.04.3844","article-title":"Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method","volume":"24","author":"Normolle","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib29","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1634\/theoncologist.2012-0483","article-title":"Ipilimumab and its toxicities: A multidisciplinary approach","volume":"18","author":"Fecher","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib30","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: A beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib31","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijrobp.2017.02.003","article-title":"Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy","volume":"98","author":"Bang","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib32","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1158\/2326-6066.CIR-13-0082","article-title":"Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma","volume":"1","author":"Barker","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib33","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/1078-0432.CCR-16-1432","article-title":"Ipilimumab with stereotactic ablative radiation therapy: Phase I results and immunologic correlates from peripheral T-cells.","volume":"23","author":"Tang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijrobp.2017.05.028","article-title":"Phase 1 study of ipilimumab combined with whole brain radiation therapy or radiosurgery for melanoma patients with brain metastases","volume":"99","author":"Williams","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib35","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ijrobp.2017.02.031","article-title":"Use of stereotactic radiosurgery in elderly and very elderly patients with brain metastases to limit toxicity associated with whole brain radiation therapy","volume":"98","author":"Chen","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib36","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0360-3016(99)00507-6","article-title":"Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05","volume":"47","author":"Shaw","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib37","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/1479-5876-9-204","article-title":"A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma","volume":"9","author":"Hamid","year":"2011","journal-title":"J Transl Med"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib38","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/PPO.0b013e31824b2890","article-title":"Treatment of melanoma brain metastases: A new paradigm","volume":"18","author":"Carlino","year":"2012","journal-title":"Cancer J"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib39","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/sj.bjc.6605622","article-title":"Determinants of survival in patients with brain metastases from cutaneous melanoma","volume":"102","author":"Staudt","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib40","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: Impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib41","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nn.3161","article-title":"Immune surveillance in the central nervous system","volume":"15","author":"Ousman","year":"2012","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib43","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.cell.2017.05.005","article-title":"Interferon-\u03b3 drives Treg fragility to promote anti-tumor immunity","volume":"169","author":"Overacre-Delgoffe","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib44","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.13100","article-title":"Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: An early marker of resistance to immune control?","volume":"171","author":"Chevolet","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ijrobp.2017.11.029_bib45","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/cncr.21283","article-title":"The predictive value of CD8, CD4, CD68, and human leukocyte antigen-d-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase","volume":"104","author":"Piras","year":"2005","journal-title":"Cancer"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301617341512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301617341512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T16:54:57Z","timestamp":1659977697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301617341512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0360301617341512"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2017.11.029","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1 Dose Escalation Trial of Ipilimumab and\u00a0Stereotactic Body Radiation Therapy in Metastatic Melanoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2017.11.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}